Target group - Primary target group remains as girls aged 9–14 years for the prevention of cervical cancer. - Vaccination of secondary target populations, e.g. females aged ≥15 years, boys, older males or MSM, is recom­mended only if this is feasible and affordable, and does not divert resources from vaccination of the primary target population or effective cervical cancer screening programmes. Vaccination schedule - Two doses preferably given 12-months apart, with a 3rd dose for immunocompromised or HIV-infected populations where possible. - Alternative single-dose schedule as an off-label option. This has compa­rable efficacy and duration of protection, may offer programme advantages, be more efficient and affordable, and contribute to improved coverage. Choice of vaccine - All currently licensed vaccines offer comparable protection from cervical cancer - For single-dose schedules, HPV vaccines with data on efficacy or immunobridging are advised. As of today, these are Cervarix ® (GSK), G